Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7,228 | 1 | 83.5% |
| Food and Beverage | $1,083 | 17 | 12.5% |
| Travel and Lodging | $341.21 | 1 | 3.9% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,315 | 3 | $0 (2024) |
| Adaptive Biotechnologies Corporation | $1,098 | 11 | $0 (2023) |
| Amgen Inc. | $239.32 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $53.98 | 2 | Amgen Inc. ($34.02) |
| 2023 | $7,708 | 5 | Novartis Pharmaceuticals Corporation ($7,228) |
| 2022 | $676.30 | 9 | Adaptive Biotechnologies Corporation ($618.38) |
| 2021 | $147.38 | 2 | Amgen Inc. ($147.38) |
| 2020 | $66.29 | 1 | Novartis Pharmaceuticals Corporation ($66.29) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/15/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: Oncology | ||||||
| 02/13/2024 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $34.02 | General |
| Category: Oncology | ||||||
| 03/09/2023 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $341.21 | General |
| Category: ONCOLOGY | ||||||
| 03/09/2023 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $62.31 | General |
| Category: ONCOLOGY | ||||||
| 03/09/2023 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $49.53 | General |
| Category: ONCOLOGY | ||||||
| 03/09/2023 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $27.00 | General |
| Category: ONCOLOGY | ||||||
| 02/28/2023 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | — | Cash or cash equivalent | $7,228.34 | Research |
| Study: KYMRIAH Study Related Case Report Writing Support • Category: Oncology | ||||||
| 11/18/2022 | Adaptive Biotechnologies Corporation | — | Food and Beverage | In-kind items and services | $111.16 | General |
| 11/18/2022 | Adaptive Biotechnologies Corporation | — | Food and Beverage | In-kind items and services | $99.73 | General |
| 11/18/2022 | Adaptive Biotechnologies Corporation | — | Food and Beverage | In-kind items and services | $68.47 | General |
| 11/17/2022 | Adaptive Biotechnologies Corporation | — | Food and Beverage | In-kind items and services | $102.70 | General |
| 11/17/2022 | Adaptive Biotechnologies Corporation | — | Food and Beverage | In-kind items and services | $81.86 | General |
| 11/17/2022 | Adaptive Biotechnologies Corporation | — | Food and Beverage | In-kind items and services | $78.41 | General |
| 11/17/2022 | Adaptive Biotechnologies Corporation | — | Food and Beverage | In-kind items and services | $76.05 | General |
| 10/04/2022 | Amgen Inc. | Blincyto (Biological), RIABNI | Food and Beverage | In-kind items and services | $31.71 | General |
| Category: Oncology | ||||||
| 05/11/2022 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: Oncology | ||||||
| 07/22/2021 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $119.90 | General |
| Category: Oncology | ||||||
| 06/08/2021 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $27.48 | General |
| Category: Oncology | ||||||
| 02/20/2020 | Novartis Pharmaceuticals Corporation | KYMRIAH (Biological) | Food and Beverage | In-kind items and services | $66.29 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| KYMRIAH Study Related Case Report Writing Support | Novartis Pharmaceuticals Corporation | $7,228 | 1 |
About April Rahrig
April Rahrig is a Pediatric Hematology-Oncology healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/25/2013. The National Provider Identifier (NPI) number assigned to this provider is 1942542253.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, April Rahrig has received a total of $8,652 in payments from pharmaceutical and medical device companies, with $53.98 received in 2024. These payments were reported across 19 transactions from 3 companies. The most common payment nature is "" ($7,228).
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Indianapolis, IN
- Active Since 03/25/2013
- Last Updated 11/06/2020
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1942542253
Products in Payments
- KYMRIAH (Drug) $7,248
- clonoSEQ (Device) $480.05
- Blincyto (Biological) $239.32
- KYMRIAH (Biological) $66.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Indianapolis
Dr. Amy Shapiro, Md, MD
Pediatric Hematology-Oncology — Payments: $402,834
Dr. Bassem Razzouk, Md, MD
Pediatric Hematology-Oncology — Payments: $46,110
W. Scott Goebel, Md, MD
Pediatric Hematology-Oncology — Payments: $42,209
Melissa Bear, M.d, M.D
Pediatric Hematology-Oncology — Payments: $26,181
Dr. Kerry Hege, M.d, M.D
Pediatric Hematology-Oncology — Payments: $19,106
Dr. Steven Rhodes, M.d., Ph.d, M.D., PH.D
Pediatric Hematology-Oncology — Payments: $7,263